Skip to main navigation Skip to search Skip to main content

Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia

Research output: Contribution to journal › Article › peer-review

Abstract

As the treatment paradigm for Waldenström macroglobulinemia (WM) continues to evolve, the debate surrounding the prioritization of depth of response versus disease control as therapeutic goals gains significant relevance. However, the impact of depth of response from fixed-duration therapy on overall survival (OS) was unclear. This multicenter study evaluated the prognostic impact of depth of response using a landmark survival analysis. A total of 440 patients with WM treated with frontline fixed-duration regimens were included. Attaining a major response (MaR) was associated with superior outcomes, including significantly longer OS. The estimated 5-year PFS rates for patients with MaR at 6 months versus not were 50% versus 32%, respectively, p < 0.001, and the estimated 5-year OS rates for patients with MaR at 6 months versus not were 89% versus 70%, respectively, p < 0.001. In a multivariable analysis, MaR at 6 months was independently associated with superior PFS (HR 0.66, p = 0.007) and OS (HR 0.28, p < 0.001). Similar results were seen when considering deeper responses (CR + VGPR vs. PR). Depth of response at 6 months is an important prognostic marker in WM and an independent predictor of PFS and OS. These results support its utilization as a suitable endpoint in clinical studies in WM.

Original languageEnglish (US)
Pages (from-to)980-986
Number of pages7
JournalAmerican journal of hematology
Volume100
Issue number6
DOIs
StatePublished - Jun 2025

Keywords

  • Waldenstrom Macroglobulinemia
  • fixed-duration
  • lymphoplasmacytic lymphoma
  • outcomes
  • treatment

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia'. Together they form a unique fingerprint.

Cite this